Citadel Advisors
IQMD

Citadel Advisors’s Intelligent Medicine Acquisition Corp. Class A Common Stock IQMD Stock Holding History

Citadel Advisors’s Portfolio IQMD Stock Details IQMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-600,000
Closed -$6M – 14614
2022
Q1 		$6M Hold
600,000
– – ﹤0.01% 3831
2021
Q4 		$5.94M Buy
+600,000
New +$5.93M ﹤0.01% 4001

Other funds holding IQMD

SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Citadel Advisors's IQMD Position: Q2 2022 in Review

Citadel Advisors sold out of Intelligent Medicine Acquisition Corp. Class A Common Stock (IQMD) in Q2 2022, closing a stake of 600,000 shares — an estimated $6M sold.

Citadel Advisors first reported a position in IQMD in Q4 2021 and held it in 2 quarters. The position peaked at $6M in Q1 2022. 58 funds tracked by Wall St. Rank hold IQMD as of Q2 2022.

  • Citadel Advisors reported no remaining Intelligent Medicine Acquisition Corp. Class A Common Stock position as of Q2 2022 after selling out during the quarter.
  • Citadel Advisors sold 600,000 Intelligent Medicine Acquisition Corp. Class A Common Stock shares in Q2 2022, an estimated $6M.
  • Citadel Advisors first reported a position in Intelligent Medicine Acquisition Corp. Class A Common Stock in Q4 2021 and held it in 2 quarters.
  • Citadel Advisors's Intelligent Medicine Acquisition Corp. Class A Common Stock position peaked at $6M in Q1 2022.
  • 58 funds tracked by Wall St. Rank held Intelligent Medicine Acquisition Corp. Class A Common Stock as of Q2 2022.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.